In MCF-7 BUS breast cancer cells, MPA increased the MTT-based proliferation readout over 120 hours. The reported EC50 was 0.1 ± 0.03 pM (SEM), an assay-specific response rather than a receptor-binding measurement. The maximal response was not significantly different from estradiol, and 1 nM MPA did not significantly change the response to 1 nM estradiol. [2]
MPA activates progesterone receptor-dependent transcription
Cell-based study · T47Dco breast cancer cells; HeLa and T47D-Y derivatives expressing PR-A or PR-B [1]
MPA activated a PRE2/luciferase reporter. Relative activity versus R5020 depended on cell background and PR isoform; engineered T47D-Y cells showed lower MPA activity.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.01–1000 nmol/l
- Exposure duration
- 20 hours (Methods and Figure 2 caption)
- Method
- Cell treatment followed by luciferase/Renilla reporter measurement.
- Vehicle
- Ethanol
Methods and source locations
Compound reported in the paper: Medroxyprogesterone acetate; Compound label in the paper: MPA
Reported research material; no Adooq lot equivalence established.
Materials and methods: Transcription assays; Results: Synthetic progestins and progesterone receptor; Figure 2a–e
PRE2/luciferase transcription normalized to Renilla and 1 µmol/l R5020: Luciferase reporter; triplicate; mean ± standard error — Figure 2a–e and associated Results; Transcription assays
Androgen-responsive endogenous gene regulation by MPA
Cell-based study · PR-negative, engineered AR-positive Y-AR human breast cancer cells; parental T47D-Y controls [1]
MPA and DHT shared substantial gene regulation, including F3, MAF-B and KRT4 induction. The DHT-responsive p57 transcript was not similarly induced by MPA.
Literature-Reported Treatment Conditions
- Treatment concentration
- MPA: 10 nmol/l or 1 µmol/l; DHT and progesterone comparators: 10 nmol/l
- Exposure duration
- 6 hours
- Method
- Affymetrix expression profiling with selected transcript RT-PCR confirmation.
- Vehicle
- Ethanol
Methods and source locations
Compound reported in the paper: Medroxyprogesterone acetate; Compound label in the paper: MPA
Reported research material; no Adooq lot equivalence established.
Expression profiling and RT-PCR methods; Results: Expression profiling of medroxyprogesterone acetate versus dihydrotestosterone; Figure 7a–b; Y-AR validation in Figure 6
Endogenous androgen-responsive transcript regulation: Microarray selection: ≥2-fold, P<0.05; RT-PCR confirmation with GAPDH control — Figure 7a–b and associated Results; Expression profiling and RT-PCR methods
MPA increases MTT signal in MCF-7 BUS cells
Cell-based study · Authenticated, mycoplasma-negative human MCF-7 BUS breast cancer cells [2]
MPA increased MTT-based proliferation readout with a reported EC50 of 0.1 ± 0.03 pM (SEM). Its fitted maximal response was not significantly different from estradiol. Adding 1 nM MPA did not significantly change the estradiol response.
Literature-Reported Treatment Conditions
- Treatment concentration
- Concentration-response series; 1 nM MPA in the equimolar estradiol comparison
- Exposure duration
- 120 hours total; treatment renewed after 72 hours
- Method
- MTT cell viability assay used as a proliferation readout.
- Vehicle
- Vehicle control; solvent not specified in the acquired article
- Co-treatment
- Separate comparison: 1 nM MPA with 1 nM estradiol
- Reported limits
- Full concentration series is plotted rather than enumerated in the methods. Exact independent experiment number for each panel is not supplied; general methods state at least three independent experiments.
Methods and source locations
Compound reported in the paper: Medroxyprogesterone acetate; Compound label in the paper: MPA
Reported research material; no Adooq lot equivalence established.
Methods 2.1, 2.2, 2.8; Results 3.1; Figure 1A–D and embedded table
MTT-based proliferation response: Non-linear regression; ≥3 independent experiments per general Methods 2.8 — Figure 1A embedded table; Methods 2.2 and 2.8
Fitted maximal MTT response relative to estradiol maximum set to 100%: Non-linear regression; Figure 1B shows no significant efficacy differences — Figure 1A embedded table and Figure 1B
MTT response with estradiol and MPA: Figure caption reports Dunnett comparison to estradiol alone — Figure 1D and caption